Multifunctional polymeric micelle-based nucleic acid delivery: Current advances and future perspectives
Source abstract
Abstract
Abstract Nucleic acid (NA) therapeutics are a rapidly growing class of biomedicines with the ability to manipulate gene expression in potent and specific manner, and with the enormous potential in the treatment of life-threatening diseases. Sensibility towards physiological barriers that compromises their therapeutic applicability led to design of highly functional polymeric micelles (PMs). PMs constitute colloidal polymer-based core-shell structures composed of amphiphilic building blocks, serving as efficient NA delivery platforms based on their ability to accommodate NAs mainly through electrostatic-driven complexation processes. Facile manipulation of polymeric building blocks offers the possibility to tune crucial parameters indispensable for NA protection and efficacious delivery to targeted sites. Ordered core-shell structure enables incorporation of other therapeutic/diagnostic agents, presenting possibility for combined therapy and theranostics. In this review we highlight design, characterization, major developments and latest applications of PMs, and provide a critical overview of current challenges and future prospects of PMs as potential NA-based delivery systems aimed at improved NA therapies.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Overcoming cancer therapeutic bottleneck by drug repurposing10.1038/s41392-020-00213-8 ↗
2. Makurvet · Biologics vs. small molecules: Drug costs and patient access · 2021 · 9
3. A review of cancer immunotherapy: from the past, to the present, to the future10.3747/co.27.5223 ↗
4. Therapeutic nucleic acids: current clinical status10.1111/bcp.12987 ↗
5. Damase, T.R., et al., The Limitless Future of RNA Therapeutics.2021. 9(161).10.3389/fbioe.2021.628137 ↗
6. The approved gene therapy drugs worldwide: from 1998 to 201910.1016/j.biotechadv.2019.107502 ↗
7. Challenges in DNA Delivery and Recent Advances in Multifunctional Polymeric DNA Delivery Systems10.1021/acs.biomac.7b00803 ↗
8. Hackett, P., T. Starr, and L. Cooper, Chapter 5. Risks of Insertional Mutagenesis by DNA Transposons in Cancer Gene Therapy. 2015.10.1016/B978-0-12-800563-7.00005-1 ↗
9. Design concepts of polyplex micelles for in vivo therapeutic delivery of plasmid DNA and messenger RNA10.1002/jbm.a.36614 ↗
10. Block Copolymer Micelles in Nanomedicine Applications10.1021/acs.chemrev.8b00199 ↗
11. RNA interference and its role in cancer therapy
12. The current state and future directions of RNAi-based therapeutics10.1038/s41573-019-0017-4 ↗
13. The powerful world of antisense oligonucleotides: From bench to bedside10.1002/wrna.1594 ↗
14. Nonviral Nanoparticles for CRISPR-Based Genome Editing: Is It Just a Simple Adaption of What Have Been Developed for Nucleic Acid Delivery?10.1021/acs.biomac.9b00783 ↗
15. Engineered materials for in vivo delivery of genome-editing machinery10.1038/s41578-019-0145-9 ↗
16. Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases10.7150/thno.43360 ↗
17. Current RNA-based Therapeutics in Clinical Trials10.2174/1566523219666190719100526 ↗
18. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials10.1016/j.vaccine.2019.04.074 ↗
19. Kyriakopoulos, C.E., et al., Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer.2020. 26(19): p. 5162-5171.10.1158/1078-0432.CCR-20-0945 ↗
20. DNA Vaccines-How Far From Clinical Use?10.3390/ijms19113605 ↗
21. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives10.1186/s13046-019-1154-7 ↗
22. Shimabukuro, T.T., et al., Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons.2021.10.1097/01.aoa.0000796052.11696.42 ↗
23. A Thermostable mRNA Vaccine against COVID-1910.1016/j.cell.2020.07.024 ↗
24. Optimal conditions for uptake of exogenous DNA by Chinese hamster lung cells deficient in hypoxanthine-guanine phosphoribosyltransferase10.1016/0005-2787(75)90350-0 ↗
25. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system10.1016/S0021-9258(18)61209-8 ↗
26. Water-Soluble Block Polycations as Carriers for Oligonucleotide Delivery10.1021/bc00036a001 ↗
27. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs10.1038/s41565-019-0591-y ↗
28. Scott · Givosiran: First Approval. Drugs · 2020 · 80 · 335
29. Red-blood-cell-mimetic gene delivery systems for long circulation and high transfection efficiency in ECs10.1039/C8TB01789A ↗
30. Gillmore · CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis · 2021 · 385 · 493
31. Re-Engineering RNA Molecules into Therapeutic Agents10.1021/acs.accounts.8b00650 ↗
32. Selvam · Therapeutic potential of chemically modified siRNA: Recent trends · 2017 · 90 · 665
33. Aptamers Chemistry: Chemical Modifications and Conjugation Strategies10.3390/molecules25010003 ↗
34. Chemical Modifications in RNA Interference and CRISPR/Cas Genome Editing Reagents10.1007/978-1-0716-0290-4_2 ↗
35. Non-viral vectors for gene-based therapy10.1038/nrg3763 ↗
36. Xin, X., et al., Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy.2020. 6(46): p. eabd6764.10.1126/sciadv.abd6764 ↗
37. Gene therapy returns to centre stage10.1038/nature15818 ↗
38. Polymeric Carriers for Nucleic Acid Delivery: Current Designs and Future Directions10.1021/acs.biomac.9b00999 ↗
39. Polymeric-Micelle-Based Nanomedicine for siRNA Delivery10.1002/ppsc.201200061 ↗
40. Polyion complex micelle formation from double-hydrophilic block copolymers composed of charged and non-charged segments in aqueous media10.1038/pj.2017.67 ↗
41. Polyion complex micelles as vectors in gene therapy–pharmacokinetics and in vivo gene transfer10.1038/sj.gt.3301665 ↗
42. Micelleplexes as nucleic acid delivery systems for cancer-targeted therapies10.1016/j.jconrel.2020.04.041 ↗
43. Wang, H., et al., Cationic micelle: A promising nanocarrier for gene delivery with high transfection efficiency.2019. 21(7): p. e3101.10.1002/jgm.3101 ↗
44. Nanomedicine in osteosarcoma therapy: Micelleplexes for delivery of nucleic acids and drugs toward osteosarcoma-targeted therapies10.1016/j.ejpb.2019.10.013 ↗
45. Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue10.1002/smll.201600925 ↗
46. Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer10.1016/j.canlet.2013.09.037 ↗
47. Self-assembled siRNA–PLGA conjugate micelles for gene silencing10.1016/j.jconrel.2010.12.007 ↗
48. Recent progress on DNA block copolymer10.1016/j.cclet.2017.08.022 ↗
49. pH-responsive DNA nanomicelles for chemo-gene synergetic therapy of anaplastic large cell lymphoma10.7150/thno.45803 ↗
50. Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment10.2147/IJN.S304526 ↗
51. Development of cholesteryl peptide micelles for siRNA delivery10.1016/j.jconrel.2013.07.033 ↗
52. Polymeric Delivery of Therapeutic Nucleic Acids10.1021/acs.chemrev.0c00997 ↗
53. Recent advances in the redox-responsive drug delivery nanoplatforms: A chemical structure and physical property perspective10.1016/j.msec.2020.111536 ↗
54. Tumor microenvironment responsive drug delivery systems
55. Recent advances in co-delivery systems based on polymeric nanoparticle for cancer treatment. Artificial Cells
56. Long Circulating Polymeric Nanoparticles for Gene/Drug Delivery10.2174/1389200219666171207120643 ↗
57. Limitations and niches of the active targeting approach for nanoparticle drug delivery
58. Pluronic-based nanovehicles: Recent advances in anticancer therapeutic applications10.1016/j.ejmech.2020.112526 ↗
59. Rational design and latest advances of codelivery systems for cancer therapy10.1016/j.mtbio.2020.100056 ↗
60. Multifunctional polymeric micelles for delivery of drugs and siRNA10.3389/fphar.2014.00077 ↗
61. Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval10.1016/j.addr.2020.09.009 ↗
62. Polycation Architecture and Assembly Direct Successful Gene Delivery: Micelleplexes Outperform Polyplexes via Optimal DNA Packaging10.1021/jacs.9b06218 ↗
63. Influence of Nano-Carrier Architecture on in Vitro siRNA Delivery Performance and in Vivo Biodistribution: Polyplexes vs Micelleplexes10.1021/nn102540y ↗
64. Micelleplex-based nucleic acid therapeutics: From targeted stimuli-responsiveness to nanotoxicity and regulation10.1016/j.ejps.2020.105461 ↗
65. Magalhães, M., A. Figueiras, and F. Veiga, Chapter 7 - Smart micelleplexes: An overview of a promising and potential nanocarrier for alternative therapies, in Design and Development of New Nanocarriers, A.M. Grumezescu, Editor. 2018, William Andrew Publishing. p. 257-291.10.1016/B978-0-12-813627-0.00007-7 ↗
66. Amphiphilic block copolymers in drug delivery: advances in formulation structure and performance10.1080/17425247.2018.1529756 ↗
67. Polymeric micelles – a new generation of colloidal drug carriers10.1016/S0939-6411(99)00039-9 ↗
68. Cationic, amphiphilic copolymer micelles as nucleic acid carriers for enhanced transfection in rat spinal cord10.1016/j.actbio.2016.02.013 ↗
69. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer10.1021/acs.molpharmaceut.7b00355 ↗
70. Messenger RNA delivery of a cartilage-anabolic transcription factor as a disease-modifying strategy for osteoarthritis treatment10.1038/srep18743 ↗
71. Elaboration on the Distribution of Hydrophobic Segments in the Chains of Amphiphilic Cationic Polymers for Small Interfering RNA Delivery10.1021/acsami.7b07337 ↗
72. Design of Free Triblock Polylysine- b-Polyleucine- b-Polylysine Chains for Gene Delivery10.1021/acs.biomac.8b00287 ↗
73. Cao, Z., et al., The Codelivery of siRNA and QDs by pH-Responsive Micelle for Hepatoma Cancer Cells. 2019. 10(1194).10.3389/fphar.2019.01194 ↗
74. Messenger RNA-based therapeutics for brain diseases: An animal study for augmenting clearance of beta-amyloid by intracerebral administration of neprilysin mRNA loaded in polyplex nanomicelles10.1016/j.jconrel.2016.06.001 ↗
75. Enhancement of Motor Function Recovery after Spinal Cord Injury in Mice by Delivery of Brain-Derived Neurotrophic Factor mRNA10.1016/j.omtn.2019.06.016 ↗
76. Co-encapsulation of Cas9 mRNA and guide RNA in polyplex micelles enables genome editing in mouse brain10.1016/j.jconrel.2021.02.026 ↗
77. Polyplex nanomicelle delivery of self-amplifying RNA vaccine10.1016/j.jconrel.2021.09.008 ↗
78. Polylactide-Based Reactive Micelles as a Robust Platform for mRNA Delivery
79. Codelivery for Paclitaxel and Bcl-2 Conversion Gene by PHB-PDMAEMA Amphiphilic Cationic Copolymer for Effective Drug Resistant Cancer Therapy10.1002/mabi.201700186 ↗
80. Redox-Responsive Efficient DNA and Drug Co-Release from Micelleplexes Formed from a Fluorescent Cationic Amphiphilic Polymer10.1021/acs.langmuir.9b02921 ↗
81. Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery10.1016/j.biomaterials.2008.09.025 ↗
82. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer10.7150/thno.53828 ↗
83. Enhanced Stability and Knockdown Efficiency of Poly(ethylene glycol)-b-polyphosphoramidate/siRNA Micellar Nanoparticles by Co-condensation with Sodium Triphosphate10.1007/s11095-011-0408-7 ↗
84. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA–PCL–PDMAEMA triblock copolymers10.1016/j.biomaterials.2009.11.077 ↗
85. The use of cationic MPEG-PCL-g-PEI micelles for co-delivery of Msurvivin T34A gene and doxorubicin10.1016/j.biomaterials.2014.02.010 ↗
86. Amphiphilic Biodegradable PEG-PCL-PEI Triblock Copolymers for FRET-Capable in Vitro and in Vivo Delivery of siRNA and Quantum Dots10.1021/mp400744a ↗
87. Enhancing in vivo circulation and siRNA delivery with biodegradable polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) copolymers10.1016/j.biomaterials.2012.05.055 ↗
88. Prolongation of life in rats with malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-penetrating peptide-modified micelles10.1021/mp400644e ↗
89. Development of cell-penetrating peptide-modified MPEG-PCL diblock copolymeric nanoparticles for systemic gene delivery10.1016/j.ijpharm.2010.06.028 ↗
90. Nucleic Acid Delivery with α-Tocopherol-Polyethyleneimine-Polyethylene Glycol Nanocarrier System10.2147/IJN.S259724 ↗
91. Cationic micelle-based siRNA delivery for efficient colon cancer gene therapy10.1186/s11671-019-2985-z ↗
92. A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery10.1016/j.biomaterials.2012.02.041 ↗
93. Simultaneous delivery of gene and chemotherapeutics via copolymeric micellar nanoparticles to overcome multiple drug resistance to promote synergistic tumor suppression10.1177/0885328219839254 ↗
94. Biodegradable copolymers with identical cationic segments and their performance in siRNA delivery10.1016/j.jconrel.2012.01.015 ↗
95. Acid-activatible micelleplex delivering siRNA-PD-L1 for improved cancer immunotherapy of CDK4/6 inhibition
96. Synergistic Therapy of Doxorubicin and miR-129-5p with Self-Cross-Linked Bioreducible Polypeptide Nanoparticles Reverses Multidrug Resistance in Cancer Cells10.1021/acs.biomac.6b00141 ↗
97. Co-Delivery of Doxorubicin and Anti-BCL-2 siRNA by pH-Responsive Polymeric Vector to Overcome Drug Resistance in In Vitro and In Vivo HepG2 Hepatoma Model10.1021/acs.biomac.8b00272 ↗
98. Triple-Layered pH-Responsive Micelleplexes Loaded with siRNA and Cisplatin Prodrug for NF-Kappa B Targeted Treatment of Metastatic Breast Cancer10.7150/thno.13515 ↗
99. Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery10.1016/j.biomaterials.2008.07.036 ↗
100. Reducible Micelleplexes are Stable Systems for Anti-miRNA Delivery in Cerebrospinal Fluid10.1021/acs.molpharmaceut.5b00933 ↗